Skip to main content
SpringerLink
Log in

Antipsychotics and Metabolics in the Post-CATIE Era

  • Chapter
  • First Online:
Behavioral Neurobiology of Schizophrenia and Its Treatment

Part of the book series: Current Topics in Behavioral Neurosciences ((CTBN,volume 4))

Abstract

Schizophrenia patients have high prevalence of cardiovascular (CV) disease risk factors and high CV mortality, with increasing concern over the contribution of antipsychotic medications to cardiometabolic risk. The design of the NIMH-sponsored Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial was driven by a need to understand the efficacy and safety differences between atypical antipsychotics, and between atypical and typical antipsychotics. The CATIE data indicated differences between olanzapine and other antipsychotics in phase 1 on the primary outcome measure, time to drug discontinuation, yet olanzapine was not superior to risperidone in the phase 2 tolerability arm, and was inferior to clozapine in the phase 2 efficacy arm. However, CATIE provided clear confirmation of the metabolic liability for olanzapine and also quetiapine, particularly on measures associated with insulin resistance: fasting triglycerides and central adiposity. Current research is focused on analyzing the adiposity-independent impact of certain antipsychotics on glucose–insulin homeostasis, and the disease-specific biological factors that predispose schizophrenia patients to metabolic dysfunction. The CATIE data also highlighted the high prevalence of metabolic disorders in chronic schizophrenia patients, and the moderating role of gender and race or ethnicity in antipsychotic-associated metabolic adverse effects. In the post-CATIE era, safety concerns remain the primary driver of antipsychotic prescribing habits. Absent compelling efficacy data that differentiates between antipsychotics for nonrefractory schizophrenia, the CATIE results reinforce the need for additional metabolically neutral antipsychotic treatment options, and the importance of ongoing physical health monitoring for schizophrenia patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allebeck P (1989) Schizophrenia: a life-shortening disease. Schizophr Bull 15:81–89

    Article  PubMed  CAS  Google Scholar 

  • American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (2004) Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 65:267–272

    Article  Google Scholar 

  • American Heart Association, National Heart, Lung, and Blood Institute, Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F (2005) Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev 13:322–327

    PubMed  Google Scholar 

  • Arranz B, Rosel P, Ramirez N, Duenas R, Fernandez P, Sanchez JM, Navarro MA, San L (2004) Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J Clin Psychiatry 65:1335–1342

    Article  PubMed  CAS  Google Scholar 

  • Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM (2007) Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298:309–316

    Article  PubMed  CAS  Google Scholar 

  • Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, Peters RJG, Jukema JW, Day NE, Kastelein JJP, Khaw K-T (2006) C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003. Atherosclerosis 187:415–422

    Article  PubMed  CAS  Google Scholar 

  • Brown S (1997) Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 171:502–508

    Article  PubMed  CAS  Google Scholar 

  • Brown S, Birtwistle J, Roe L, Thompson C (1999) The unhealthy lifestyle of people with schizophrenia. Psychol Med 29:697–701

    Article  PubMed  CAS  Google Scholar 

  • Bushe C, Holt R (2004) Prevalence of diabetes and glucose intolerance in patients with schizophrenia. Br J Psychiatry 184:67–71

    Article  Google Scholar 

  • Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S (1967) Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol–behavior relationships. Psychosom Med 29:634–642

    PubMed  CAS  Google Scholar 

  • Cohn T, Prud’homme D, Streiner D, Kameh H, Remington G (2004) Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 49:753–760

    PubMed  Google Scholar 

  • Cohn TA, Remington G, Zipursky RB, Azad A, Connolly P, Wolever TMS (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51:382–386

    PubMed  Google Scholar 

  • Colton CW, Manderscheid RW (2006) Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 3:1–14

    Google Scholar 

  • Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21–29

    PubMed  CAS  Google Scholar 

  • Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck RA, Davis SM, Hsiao JK, Stroup TS, Lieberman JA (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105:175–187

    Article  PubMed  Google Scholar 

  • De Hert MA, van Winkel R, van Eyck D, Hanssens L, Wampers M, Scheen A, Peuskens J (2006) Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 83:87–93

    Article  PubMed  Google Scholar 

  • de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ (2001) Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 285:2109–2113

    Article  PubMed  Google Scholar 

  • Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res 93:261–265

    Article  PubMed  Google Scholar 

  • Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000) Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA 283:506–511

    Article  PubMed  CAS  Google Scholar 

  • Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research Group (2003) Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 163:1077–1083

    Article  PubMed  Google Scholar 

  • Efron HY, Balter AM (1966) Relationship of phenothiazine intake and psychiatric diagnosis to glucose level and tolerance. J Nerv Ment Dis 142:555–561

    Article  PubMed  CAS  Google Scholar 

  • Epstein FH (1967) Hyperglycemia: a risk factor in coronary heart disease. Circulation 36:609–619

    Article  PubMed  CAS  Google Scholar 

  • Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  • Ford ES (2004) The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309–314

    Article  PubMed  CAS  Google Scholar 

  • Ford ES, Giles WH, Mokdad AH (2004) Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 27:2444–2449

    Article  PubMed  Google Scholar 

  • Girman CJ, Dekker JM, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, Heine RJ (2005) An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. Am J Epidemiol 162:438–447

    Article  PubMed  Google Scholar 

  • Goff DC, Sullivan L, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lamberti S, D’Agnostino RB, Stroup TS, Davis S, Lieberman JA (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE Study and matched controls. Schizophr Res 80:45–53

    Article  PubMed  Google Scholar 

  • Grundy SM, Brewer B, Cleeman JI, Smith SC, Lenfant C (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433–438

    Article  PubMed  Google Scholar 

  • Gunstad J, Bausserman L, Paul RH, Tate DF, Hoth K, Poppas A, Jefferson AL, Cohen RA (2006) C-reactive protein, but not homocysteine, is related to cognitive dysfunction in older adults with cardiovascular disease. J Clin Neurosci 13:540–546

    Article  PubMed  CAS  Google Scholar 

  • Hagg S, Lindblom Y, Mjorndal T, Adolfsson R (2006) High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 21:93–98

    Article  PubMed  Google Scholar 

  • Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7–22

    Article  Google Scholar 

  • Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J (2003) Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 64:575–579

    Article  PubMed  Google Scholar 

  • Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H (2007) Acute effects of atypical antipsychotics on whole body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 32:289–297

    Article  PubMed  CAS  Google Scholar 

  • Jeppesen J, Hein HO, Suadicani P, Gyntelberg F (1998) Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 97:1029–1036

    Article  PubMed  CAS  Google Scholar 

  • Jin H, Meyer JM, Jeste DV (2002) Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 14:59–64

    PubMed  Google Scholar 

  • Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1087

    Article  PubMed  CAS  Google Scholar 

  • Kahn R, Buse J, Ferrannini E, Stern M (2005) The metabolic syndrome: time for a critical appraisal. Diabetes Care 28:2289–2304

    Article  PubMed  Google Scholar 

  • Kannel WB, McGee DL (1979) Diabetes and cardiovascular risk factors: the Framingham study. Circulation 59:8–13

    Article  PubMed  CAS  Google Scholar 

  • Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22:841–852

    Article  PubMed  CAS  Google Scholar 

  • Koller E, Schneider B, Bennett K, Dubitsky G (2001) Clozapine-associated diabetes. Am J Med 111:716–723

    Article  PubMed  CAS  Google Scholar 

  • Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223

    Article  PubMed  CAS  Google Scholar 

  • Lorenzo C, Williams K, Hunt KJ, Haffner SM (2007) The National Cholesterol Education Program – Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 30:8–13

    Article  PubMed  Google Scholar 

  • Mackin P, Bishop D, Watkinson H, Gallagher P, Ferrier IN (2007) Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry 191:23–29

    Article  PubMed  Google Scholar 

  • Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161:1334–1349

    Article  PubMed  Google Scholar 

  • McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA (2005) Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial and comparison with national estimates from NHANES III. Schizophr Res 80:19–32

    Article  PubMed  Google Scholar 

  • McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G (2003) Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 139:802–809

    PubMed  Google Scholar 

  • Mefferd RB, Labrosse EH, Gawienowski AM, Williams RJ (1958) Influence of chlorpromazine on certain biochemical variables of chronic male schizophrenics. J Nerv Ment Dis 127:167–179

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM (2001a) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62(Suppl 27):27–34, discussion 40–41

    PubMed  CAS  Google Scholar 

  • Meyer JM (2001b) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369–374

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1–17

    Article  PubMed  Google Scholar 

  • Meyer JM, Nasrallah HA (2009) Medical illness and schizophrenia, 2nd edn. American Psychiatric Press, Washington, DC

    Google Scholar 

  • Meyer J, Loh C, Leckband SG, Boyd JA, Wirshing WC, Pierre JM, Wirshing D (2006) Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 12:5–10

    Article  PubMed  Google Scholar 

  • Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008a) Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. Schizophr Res 103:104–109

    Article  PubMed  Google Scholar 

  • Meyer JM, Davis VG, Goff DC, McEvoy JP, Nasrallah HA, Davis SM, Rosenheck RA, Daumit GL, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2008b) Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr Res 101:273–286

    Article  PubMed  Google Scholar 

  • Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao J, Swartz MS, Stroup TS, Lieberman JA (2009a) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the CATIE effective study. Biol Psychiatry 66:1013–1022

    Article  PubMed  CAS  Google Scholar 

  • Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R (2009b) The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry 70:318–325

    Article  PubMed  CAS  Google Scholar 

  • Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, Lieberman JA (2006) Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE Schizophrenia Trial sample at baseline. Schizophr Res 86:15–22

    Article  PubMed  Google Scholar 

  • Newcomer JW (2005) Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19(Suppl 1):1–93

    PubMed  CAS  Google Scholar 

  • Newcomer JW, Hennekens CH (2007) Severe mental illness and risk of cardiovascular disease. JAMA 298:1794–1796

    Article  PubMed  CAS  Google Scholar 

  • Nordestgaard BG, Benn M, Schnohr P, Tybjærg-Hansen A (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 298:299–308

    Article  PubMed  CAS  Google Scholar 

  • Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000a) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–28

    Article  PubMed  CAS  Google Scholar 

  • Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000b) Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ 321:483–484

    Article  PubMed  CAS  Google Scholar 

  • Reaven GM (1988) Banting lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595–1607

    Article  PubMed  CAS  Google Scholar 

  • Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557–1565

    Article  PubMed  CAS  Google Scholar 

  • Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E (2005) Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20–28

    Article  PubMed  CAS  Google Scholar 

  • Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, Koenig W, Libby P, Lorenzatti AJ, MacFayden JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, Group JTS (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195–2207

    Article  PubMed  CAS  Google Scholar 

  • Ryan MCM, Collins P, Thakore JH (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160:284–289

    Article  PubMed  Google Scholar 

  • Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH (2004) The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci 74:1999–2008

    Article  PubMed  CAS  Google Scholar 

  • Saari KM, Lindeman SM, Viilo KM, Isohanni MK, Jarvelin M-R, Lauren LH, Savolainen MJ, Koponen HJ (2005) A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 66:559–563

    Article  PubMed  Google Scholar 

  • Saha S, Chant D, McGrath J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 64:1123–1131

    Article  PubMed  Google Scholar 

  • Schwarz L, Munoz R (1968) Blood sugar levels in patients treated with chlorpromazine. Am J Psychiatry 125:253–255

    PubMed  CAS  Google Scholar 

  • Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420–1431

    Article  PubMed  Google Scholar 

  • Smith DA (2007) Treatment of the dyslipidemia of insulin resistance. Med Clin North Am 91:1185–1210

    Article  PubMed  CAS  Google Scholar 

  • Spelman LM, Walsh PI, Sharifi N, Collins P, Thakore JH (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24:481–485

    Article  PubMed  CAS  Google Scholar 

  • Srisurapanont M, Likhitsathian S, Boonyanaruthee V, Charnsilp C, Jarusuraisin N (2007) Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study. BMC Psychiatry 7:14

    Article  PubMed  Google Scholar 

  • Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK (2006) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611–622

    Article  PubMed  Google Scholar 

  • Suvisaari JM, Saarni SI, Perala J, Suvisaari JVJ, Harkanen T, Lonnqvist J, Reunanen A (2007) Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. J Clin Psychiatry 68:1045–1055

    Article  PubMed  CAS  Google Scholar 

  • Thakore JH, Mann JN, Vlahos I, Martin A, Reznek R (2002) Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord 26:137–141

    Article  PubMed  CAS  Google Scholar 

  • Tirupati S, Chua L-E (2007) Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ J Psychiatry 41:606–610

    Article  Google Scholar 

  • van Nimwegen LJ, Storosum JG, Blumer RM, Allick G, Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP (2008) Hepatic insulin resistance in antipsychotic naive patients with schizophrenia, a detailed study of glucose metabolism with stable isotopes. J Clin Endocrinol Metab 93:572–577

    Article  PubMed  Google Scholar 

  • Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, Shetty KT (2007) Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164:1557–1560

    Article  PubMed  Google Scholar 

  • Wannamethee SG, Shaper AG, Lennon L, Morris RW (2005) Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165:2644–2650

    Article  PubMed  Google Scholar 

  • Weiden PJ, Daniel DG, Simpson GM, Romano SJ (2003) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:1–6

    Article  Google Scholar 

  • Weiden PJ, Newcomer JW, Loebel A, Yang R, Lebovitz H (2008) Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology 33:985–994

    Article  PubMed  CAS  Google Scholar 

  • Weuve J, Ridker PM, Cook NR, Buring JE, Grodstein F (2006) High-sensitivity C-reactive protein and cognitive function in older women. Epidemiology 17:183–189

    Article  PubMed  Google Scholar 

  • Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J (2007) Active smoking and the risk of type 2 diabetes: a systematic review and meta-analysis. JAMA 298:2654–2664

    Article  PubMed  CAS  Google Scholar 

  • Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847

    Article  PubMed  CAS  Google Scholar 

  • Zhang Z-J, Yao Z-J, Liu W, Fang Q, Reynolds GP (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184:58–62

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of California, La Jolla, CA, 92093, USA

    Jonathan M. Meyer

  2. VA San Diego Healthcare System, 3350 La Jolla Village Drive (116A), San Diego, CA, 92161, USA

    Jonathan M. Meyer

Authors
  1. Jonathan M. Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jonathan M. Meyer .

Editor information

Editors and Affiliations

  1. , Dept. of Psychiatry - MC 0804, University of San Diego, Gilman Drive 9500, La Jolla, 92093, USA

    Neal R. Swerdlow

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer

About this chapter

Cite this chapter

Meyer, J.M. (2010). Antipsychotics and Metabolics in the Post-CATIE Era. In: Swerdlow, N. (eds) Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/7854_2010_45

Download citation

Publish with us

Policies and ethics

Search

Navigation